A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants

Inclusion criteria

• Healthy Chinese adults and includes participants who are between 18 to 55 years old
• BMI of 18 to 30 kg/m^2; and a total body weight ≥50 kg (110 lb) for males and ≥45 kg (99 lb) for females
• Non-smoker (no use of tobacco or nicotine products).

Exclusion criteria

• Evidence or history of clinically significant disease.
• Use of medication other than topical products without significant systemic absorption.
• Previous participantion in a clinical research study or investigational study prior to the first dosing.
• Any clinically significant abnormal laboratory test results or positive test.
• Evidence of organ dysfunction or any clinically significant deviation from normal.
• Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic).
• Standard 12-lead ECG that demonstrates clinically relevant abnormalities.
• Abnormalities in clinical laboratory tests: AST or ALT level > ULN; Total bilirubin level > ULN; ANC or ALC level > ULN.
• Positive urine drug screen, alcohol breath test, or urine cotinine test.
• Positive pregnancy test.
• Positive result for COVID-19.
• History of significant alcohol abuse or drug abuse.
• History of anaphylaxix reaction or a clinically important reaction to any drug.
• Donation of plasma within 30 days prior to dosing. Donation or loss of blood of approximately 400 mL or more within 60 days prior to dosing.
• Inability to be venipunctured and/or tolerate catheter venous access.
• Habitual use of snuff tobacco.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.